SUTRO BIOPHARMA, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-191.1M | $-227.5M | $-106.8M | $-119.2M | $-105.5M | $-32.1M | $-119.2M | $-35.3M |
| Depreciation & Amortization | $7.3M | $7.2M | $6.8M | $5.7M | $4.8M | $4.3M | $4.8M | $4.5M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $14.0M | $24.7M | $24.9M | $26.3M | $23.2M | $11.9M | $10.3M | $2.9M |
| Net Cash from Operating Activities | $-177.2M | $-191.5M | $-111.6M | $3.5M | $-81.7M | $-67.8M | $-65.0M | $12.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | $1.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $45.0M | $218.5M | $-3.9M | $-35.0M | $-97.3M | $604.0K | $-51.1M | $-80.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | $7.0K | — | — | — |
| Net Cash from Financing Activities | $44.0K | $94.1M | $137.6M | $48.3M | $3.3M | $269.2M | $-4.2M | $170.8M |
| Net Change in Cash | $-132.2M | $121.0M | $22.0M | $16.8M | $-175.7M | $202.0M | $-120.3M | $103.3M |
| Free Cash Flow | — | — | — | — | — | — | — | $11.1M |